Non-alcoholic Fatty Liver Disease (NAFLD) treated by Vitamin D (in rats this time)

Created December 2019

Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model

Clinics and Research in Hepatology and Gastroenterology, https://doi.org/10.1016/j.clinre.2019.10.007

MingMaaQiLongaFeiChenaTingZhangaWenqiaoWangb

* NAFLD is treated by Vitamin D, Omega-3, Curcumin, Silymarinm, etc. Aug 2018 * Non-alcoholic Fatty Liver Disease (4 in 10 seniors) and Vitamin D * Vitamin D reduces fatty liver problems in rats fed a high fat diet – June 2018 * Strong association of non alcoholic fatty liver disease and low vitamin D * VitaminDWiki pages with NON-ALCOHOLIC or NAFLD in title (23 pages as of Oct 2021) Items in both categories Liver and Intervention are listed here: give vitamin D and see what happens {category} Items in both categories Liver and Omega-3 are listed here: {category} --- 1. Overview Liver and vitamin D contains the following summary {include}

Objective

Non-alcoholic fatty liver disease (NAFLD) refers to an accumulation of excess fat in liver due to causes other than alcohol use. The relationship between vitamin D (VD) and NAFLD has been previously studied. Therefore, we aimed to explore the mechanism involved active VD regulating the progression of NAFLD by inhibiting cell senescence and to provide a potential approach for further nutritional treatment of NAFLD.

Methods

Following the induction with high-fat diet and intraperitoneal injection of corn oil, the successfully established NAFLD rat models were treated with 1,25(OH)2D3 at 1 μg/kg, 5 μg/kg or 10 μg/kg. Meanwhile, the levels of factors related to oxidative stress, cell senescence, the p53-p21 signaling pathway and inflammation in liver were determined. Then, cell senescence was also measured by using senescence-associated β-galactosidase (SAβ-gal) staining.

Results

It was also found that active VD increased the concentration of VD in serum and VDR in liver of NAFLD rats, and alleviated hepatic fibrosis. Besides, treatment of 1,25(OH)2D3 at 1 μg/kg, 5 μg/kg or 10 μg/kg reduced oxidative stress and inflammation, inhibited the p53-p21 signaling pathway and consequent cell senescence. Furthermore, treatment of 1,25(OH)2D3 at a dosage of 5 μg/kg made the most impact on these factors.

Conclusion

Collectively, the evidences from this study demonstrated that active VD could alleviate the development of NAFLD through blocking the p53-p21 signaling pathway, which provided a novel nutritional therapeutic insight for NAFLD.

Tags: Liver